Demonstrates tumor-selective photodynamic therapy efficacy using a novel pH-triggered photosensitizer, BDP-I.
Conventional photosensitizers for photodynamic therapy (PDT) suffer from poor tumor selectivity. Here, we develop BDP-I, a spirocyclic BODIPY-based photosensitizer that exploits the acidic tumor microenvironment (pH~6.5-6.8) to achieve selective activation....
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: